2Xideas AG Sells 24,915 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

2Xideas AG reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 26.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,654 shares of the medical equipment provider’s stock after selling 24,915 shares during the quarter. 2Xideas AG’s holdings in Lantheus were worth $6,321,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus in the 3rd quarter valued at $25,000. Kestra Investment Management LLC acquired a new stake in Lantheus in the fourth quarter worth $27,000. Summit Securities Group LLC bought a new stake in Lantheus in the fourth quarter valued at $37,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus during the third quarter valued at about $60,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock worth $6,110,806 in the last 90 days. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on LNTH. Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Trading Down 6.5 %

NASDAQ LNTH opened at $90.92 on Friday. The firm has a market capitalization of $6.23 billion, a P/E ratio of 15.13 and a beta of 0.38. The business has a fifty day simple moving average of $93.31 and a 200 day simple moving average of $96.12. Lantheus Holdings, Inc. has a 12 month low of $58.46 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.